Bobak R. Azamian, President, CEO, and Board Chair of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), filed a Form 4 on September 9, 2026, reporting the sale of 10,000 shares of common stock on September 4, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Two tranches sold: 7,100 shares were disposed of at a weighted average price of $90.27, and 2,900 shares at a weighted average price of $91.27, both on September 4, 2026.
  • Price ranges: The 7,100-share tranche was sold at prices ranging from $90.00 to $90.91; the 2,900-share tranche at prices ranging from $91.06 to $91.45.
  • Pre-planned transactions: Both sales were effected under a Rule 10b5-1 trading plan adopted by Azamian on December 9, 2025.
  • Indirect ownership after sales: Following the transactions, Azamian beneficially owned 827,991 shares indirectly through the Bobak Azamian Living Trust, established April 16, 2018.
  • Direct ownership: The filing also reports 33,421 shares held directly by the reporting person.
  • Trust role: Azamian is the trustee of the Bobak Azamian Living Trust and, according to the filing, "has voting and dispositive power with respect to these shares."

Azamian's September 2026 Share Sales Under Pre-Scheduled Trading Plan

According to the filing, Bobak R. Azamian, who serves as President, CEO, and Board Chair of Tarsus Pharmaceuticals, Inc., sold a total of 10,000 shares of common stock on September 4, 2026. The shares were held indirectly through the Bobak Azamian Living Trust, established April 16, 2018, of which Azamian is the trustee. The filing states that both sales "were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025."

The first tranche consisted of 7,100 shares sold at a weighted average price of $90.27 per share, with individual transaction prices ranging from $90.00 to $90.91. The second tranche consisted of 2,900 shares sold at a weighted average price of $91.27 per share, with prices ranging from $91.06 to $91.45. The filing notes that Azamian has undertaken to provide full information on the number of shares sold at each separate price within those ranges upon request by the issuer, any security holder, or the SEC staff.

Following the reported transactions, the filing discloses that Azamian beneficially owned 827,991 shares indirectly through the trust, in addition to 33,421 shares held directly. Both sales are recorded with transaction code "S" and are marked as disposed (D). The Form 4 was signed by Jeffrey Farrow as attorney-in-fact on September 9, 2026, and the filing indicates the box was checked confirming the transactions were made pursuant to a Rule 10b5-1(c) plan.

What Was Disclosed

The filing reports two open-market sales of Tarsus Pharmaceuticals common stock by CEO Bobak R. Azamian on September 4, 2026, totaling 10,000 shares sold through the Bobak Azamian Living Trust under a pre-established Rule 10b5-1 trading plan adopted December 9, 2025.